One-Year Update of a Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-Vmp) Versus Bortezomib, Melphalan, and Prednisone (Vmp) in Patients (Pts) with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (Ndmm): Alcyone

AuthID
P-00Q-933
29
Author(s)
Mateos, MV
·
Cavo, M
·
Suzuki, K
·
Jakubowiak, A
·
Knop, S
·
Doyen, C
·
Lucio, P
·
Nagy, Z
·
Kaplan, P
·
[+9]·
Fujisaki, T
·
Garg, M
·
Chiu, C
·
Wang, JP
·
Kudva, A
·
Kobos, R
·
Wroblewski, S
·
Qi, M
·
San Miguel, JF
·
Blade, J
Tipo de Documento
Abstract
Year published
2018
Publicado
in BLOOD, ISSN: 0006-4971
Volume: 132
Conference
60Th Annual Meeting of the American-Society-Of-Hematology (Ash), Date: DEC 01-04, 2018, Location: San Diego, CA, Patrocinadores: Amer Soc Hematol
Indexing
Publication Identifiers
Wos: WOS:000454837600210
Source Identifiers
ISSN: 0006-4971
Export Publication Metadata
Info
At this moment we don't have any links to full text documens.
Name Order Nome   Name Order Nome   Name Order Nome
1 Dimopoulos, MA;   2 Mateos, MV;   3 Cavo, M;
4 Suzuki, K;   5 Jakubowiak, A;   6 Knop, S;
7 Doyen, C;   8 Lucio, P;   9 Nagy, Z;
10 Kaplan, P;   11 Pour, L;   12 Cook, M;
13 Grosicki, S;   14 Crepaldi, AH;   15 Liberati, AM;
16 Campbell, P;   17 Shelekhova, T;   18 Yoon, SS;
19 Iosava, G;   20 Fujisaki, T;   21 Garg, M;
22 Chiu, C;   23 Wang, JP;   24 Kudva, A;
25 Kobos, R;   26 Wroblewski, S;   27 Qi, M;
28 San Miguel, JF;   29 Blade, J;